Trinity Biotech (ADR) (TRIB)
Makes rapid HIV tests, haemoglobin systems and specialty clinical diagnostics.
Something off on this page? Send us feedback.
Sells diagnostic instruments, recurring reagents and test kits, and laboratory services centered on rapid HIV testing, haemoglobin systems and specialty assays. Develops wearable biosensors and biomarker tests while distributing directly in selected markets and through partners elsewhere.
Builds and sells rapid HIV point-of-care tests, haemoglobin and HbA1c analyzers, infectious-disease and autoimmune assays, and laboratory testing services. The Immco reference laboratory serves U.S. laboratories and hospitals; sales use direct channels in selected markets and distributors, strategic partners, and nongovernmental bodies elsewhere.
Develops the CGM+ wearable biosensor, PrePsia preeclampsia-risk test, and EpiCapture urine-based test for aggressive prostate-cancer risk. Trinovium is developing direct-to-chip liquid-cooling fluids and a connected monitoring platform, but it was at technical-validation, partner-engagement, and customer-qualification stages at launch.
Existing medical products and the Immco laboratory remain subject to applicable FDA, European, UK, Canadian, CLIA, and New York laboratory requirements. Rapid-HIV demand partly depends on foreign-aid procurement, while outsourced offshore production transitions created timing variability.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Dec 31, 2025Cash & short-term investments $5.1M · Total debt $138.0M · Total assets $105.2M · Shareholders' equity −$72.0M
- Revenue
- $11.1M
- Operating income
- −$2.9M
- Net income
- −$17.5M
No dividends on record.
| Institutions | 3.27% | 33.1K ADS | |
|---|---|---|---|
| 20 holders · as of Jun 30, 2026 | |||
| Insiders | 1.63% | 16.5K ADS | |
| 2 holders · as of Apr 8, 2026 | |||
| Other | 95.10% | 962.9K ADS | |
| remainder | |||
1.01M ADS as of Sep 21, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
The share count is from the company's Dec 2022 annual report; nothing newer is on file here.
The share count has not been confirmed by a second filing; stakes use it as it stands.
Some positions are filed in underlying shares, not receipts; the ratio is unknown, so no percentage.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Hunter Associates Investment Management LLCInstitution | 2.18% | 661,210 ADS | as of Jun 30, 2026 |
Ronan O'CaoimhInsiderdirector | 1.60% | 16,207 ADS | filed Apr 8, 2026 |
Williams & Novak, LLCInstitution | 0.46% | 140,543 ADS | as of Jun 30, 2026 |
Susquehanna International Group, LLPInstitution | 0.09% | 26,859 ADS | as of Jun 30, 2026 |
Moss Adams Wealth Advisors LLCInstitution | 0.08% | 25,666 ADS | as of Jun 30, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
- Abbott
Rapid HIV, HbA1c, and CGM overlap across key testing workflows.
- Bio-Rad Laboratories
Core rival in HbA1c, haemoglobin-variant, and autoimmunity workflows.
- Dexcom
Commercial CGM benchmark for the developing multi-sensor wearable.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Trinity Biotech (ADR) | $7.40 | +0.68% | $148.8M | — | — | — | +46.0% |
| Abbott | $104.21 | +1.19% | $178.18B | 33.1 | 18.0 | 3.8 | +13.0% |
| Bio-Rad Laboratories | $382.40 | +1.34% | $10.16B | 45.7 | 37.1 | 3.9 | −0.1% |
| Dexcom | $89.95 | +0.88% | $33.65B | 35.2 | 32.1 | 6.8 | +13.1% |
| Median | 35.2 | 32.1 | 3.9 | +13.0% |